In a strategic move to strengthen domestic pharmaceutical manufacturing, Thermo Fisher Scientific and SHL Medical announced a collaboration to deliver fully integrated drug‑device solutions, significantly expanding their sterile fill‑finish and autoinjector assembly operations in Ridgefield, New Jersey. This partnership is designed to streamline combination product manufacturing, benefitting pharmaceutical and biotech companies striving for faster commercialization of injectable therapies.
The new alliance connects Thermo Fisher’s extensive sterile manufacturing capacity with SHL Medical’s innovative autoinjector platforms, ultimately creating a unified supply chain for drug‑device solutions. By integrating drug product fill‑finish with device assembly and packaging under one roof, the collaboration aims to reduce complexity, shorten development timelines, and enhance patient access to self‑administered treatments.
“This collaboration with SHL Medical and our Ridgefield expansion are important steps in helping customers meet growing demand for advanced combination products,” said Michelle Logan, Vice President of Drug Product – Steriles at Thermo Fisher Scientific. She emphasized that the integrated approach would simplify supply chains and accelerate the delivery of critical therapies to patients more efficiently than traditional fragmented models.
Under the strategic, non‑exclusive partnership, Thermo Fisher and SHL Medical will jointly support SHL’s proven Molly® autoinjector platform at the Ridgefield site, encompassing final assembly, commercial packaging, and distribution. This comprehensive support framework is expected to create a more streamlined path for customers developing drug‑device combination products, especially those targeting chronic and autoimmune diseases that rely on patient‑centric delivery systems.
Industry analysts note that demand for self‑administered therapies continues to rise, with biopharmaceutical developers increasingly seeking partners who can handle not only drug manufacturing but also the device component. By offering fully integrated drug‑device solutions, Thermo Fisher and SHL Medical position themselves as enablers of end‑to‑end product delivery, helping sponsors navigate regulatory challenges and meet market expectations for safety, quality, and speed.
SHL Medical brings decades of expertise in advanced drug delivery systems and autoinjector technology to the collaboration. The company’s integrated services span the entire device development lifecycle, from initial design and engineering through production and regulatory support, ensuring reliable and user‑friendly solutions for partners worldwide.
“Working with Thermo Fisher represents a significant milestone for SHL Medical and for the customers we serve globally,” said Markus Puusepp, Chief Growth Officer at SHL Medical. He highlighted the synergistic potential of combining SHL’s autoinjector platforms with Thermo Fisher’s sterile manufacturing network to support the growing needs of patients and developers alike.
The Ridgefield facility, acquired by Thermo Fisher from Sanofi in September 2025, is central to the company’s strategy to enhance its U.S. manufacturing footprint and offer robust solutions for combination product manufacturing. By strengthening this site’s capabilities for pre‑filled syringe (PFS) operations, autoinjector assembly, and commercial packaging, Thermo Fisher aims to meet increasing customer demand across multiple therapeutic areas.
Industry observers point out that domestic capacity for complex drug‑device therapies has become a strategic priority, especially in light of global supply chain disruptions and regulatory emphasis on resilient manufacturing. The integrated approach taken by Thermo Fisher and SHL Medical aligns with broader trends in the life sciences sector, where biopharmaceutical companies seek partners that can oversee the entire manufacturing continuum from drug formulation to device delivery.
In addition to Ridgefield, Thermo Fisher’s global sterile network includes facilities in Allentown, Pennsylvania; Horsham, United Kingdom; and planned capacity expansions in Greenville, North Carolina, and the Asia‑Pacific region. These investments further reinforce the company’s ability to support global customers with scalable and compliant manufacturing solutions, particularly for complex combination products.
The collaboration also reflects a broader shift in the pharmaceutical landscape toward integrated drug‑device solutions, where drug manufacturers partner with device specialists to deliver complete therapeutic systems. Such integrated services are increasingly valued by biotech and pharmaceutical sponsors, who benefit from reduced project risk, faster time to market, and simplified regulatory pathways.
Overall, the strategic partnership between Thermo Fisher Scientific and SHL Medical represents a significant advancement in combination product manufacturing. By uniting sterile drug production with sophisticated autoinjector assembly and packaging, the collaboration aims to deliver more efficient, reliable, and patient‑focused drug‑device solutions to the global healthcare market.
Thermo Fisher’s mission to support life sciences innovation and enhance patient health underpins the alliance, positioning the company as a key partner in the evolving landscape of integrated pharmaceutical and medical device manufacturing. As demand for patient‑centric therapies grows, collaborations like this are likely to play an increasingly vital role in shaping the future of drug delivery.
